Inactive Instrument

Biostage Inc Stock price Nasdaq

Equities

US09074M1036

Advanced Medical Equipment & Technology

Sales 2021 - Sales 2022 - Capitalization 66.96M
Net income 2021 -7M Net income 2022 -6M EV / Sales 2021 -
Net cash position 2021 1.3M Net cash position 2022 1.11M EV / Sales 2022 -
P/E ratio 2021
-2.9 x
P/E ratio 2022
-10.3 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 50.5%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 49 21-08-31
Chief Executive Officer 60 12-05-02
President 52 18-05-30
Members of the board TitleAgeSince
Chief Executive Officer 60 12-05-02
Director/Board Member 59 23-04-04
Director/Board Member 69 18-03-28
More insiders
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company. It uses the patient’s own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma or birth defects. Its Cellframe/Cellspan technology utilizes a biocompatible scaffold that is seeded with the patient’s own cells to create a Cellspan implant. Its product candidate includes Cellspan Esophageal Implant, Cellspan Bronchial Implants and Cellspan Tracheal Implants. It is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection. Cellspan Tracheal Implants allow for the reconstruction of any portion of the trachea, potentially restoring its functional integrity. It is also launching a consumer medicine division to promote advanced anti-aging technology and products in China.
More about the company